BioCentury
ARTICLE | Clinical News

Noven starts Phase III MethyPatch trial

October 29, 2001 8:00 AM UTC

NOVN said it began a second double-blind, placebo-controlled Phase III trial of its MethyPatch methylphenidate to treat ADHD in up to 200 children. NOVN also reported results of a double-blind, placebo-controlled Phase III study comparing MethyPatch once-daily to placebo transdermal systems in more than 200 children ages 6-12 with ADHD. Using teacher ratings of patient behavior using the IOWA Conners Rating Scale, the primary endpoint, no statistically significant improvements were observed. The product did show a statistically significant improvement in ADHD symptoms compared to placebo, as measured by parents and teachers, NOVN said. Data were presented at the American Academy of Child & Adolescent Psychiatry. ...